Novartis opens the world's largest centre for respiratory research in Horsham, UK
"We believe that the Novartis Respiratory Research Centre offers great promise for the discovery and development of the next generation of treatments for sufferers of respiratory disease," said Paul Herrling, worldwide Head of Research at Novartis Pharma. "It builds on the breakthrough science that has led to innovative products such as Foradil®, the first and only fast-acting, long-lasting bronchodilator, and Xolair®, our novel anti-IgE currently in development for allergic asthma and rhinitis."
Respiratory illnesses are growing at an alarming rate. Nearly 150 million people around the world are afflicted with asthma today. In less than twenty years this number will double to roughly the current population of the United States.1 Other conditions such as COPD, which kills 2.5 million people annually, is the fourth leading cause of death in the developed world.1,2
"The need for this type of vital research is illustrated by the recent AIRE study that shows, despite receiving treatment, 46% of asthma sufferers still have day-time symptoms, when the goal should be elimination and reduction of these symptoms", said Professor Peter Barnes, Director of the Department of Thoracic Medicine at the National Heart and Lung Institute, London, who spoke at the opening.
The Novartis Respiratory Research Centre has attracted leading experts in the field, and will be led by Professor John Westwick, formerly head of Pharmacy and Pharmacology at Bath University, UK. Professor Westwick is best known for his research and extensive publications on the molecular mechanisms of inflammation and pioneering studies into the functional significance of ion channels in inflammatory cells.
Most read news
Topics
Organizations
Other news from the department science
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.